|
||||||
|
 | |
| |
| Expression of this gene in the resistant group across all datasets and cell types |
| Significant ligand-receptor pairs related to this gene (This gene does not contain this module) |
| |
| |
| |
| Acts as a transcription factor (This gene does not contain this module) |
|
Gene: PTGS2 |
Summary for PTGS2 |
| Gene information | Gene symbol | PTGS2 | Ensembl ID | ENSG00000073756 |
| Entrez ID | 5743 | |
| Gene name | prostaglandin-endoperoxide synthase 2 | |
| Synonyms | COX2 | |
| Gene type | protein_coding | |
| UniProtAcc | P35354 |
Top |
Dataset with differentially expressed gene: PTGS2 |
 Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group. |
| Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE164551 | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Immunotherapy | CAR-T | NA | Mono/Macro | -0.668268 | 1.68e-24 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Neutrophils | -1.8188 | 0.00e+00 |
GSE207422_Tor | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Neutrophils | 0.835048 | 2.83e-07 |
GSE189460 | patients | Bone marrow aspirate | Multiple myeloma | Multiple myeloma (MM) | Targeted therapy | bortezomib + melphalan + prednisolone | pre | Mono/Macro | -0.715368 | 0.00e+00 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre | Mono/Macro | 0.469291 | 1.16e-10 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | post | Mono/Macro | -0.465221 | 0.00e+00 |
GSE175716 | PDX | Tumor tissue | Liver cancer | Advanced hepatocellular carcinoma | Targeted therapy | sorafenib | NA | Malignant cells | -0.907255 | 4.63e-31 |
Top |
Expression of PTGS2 in the resistant group across all datasets and cell types |
| Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.) |
 |
Top |
Significant ligand-receptor pairs related to PTGS2 |
| This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.) |
Top |
Known drug resistance mechanisms of this gene |
| This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information. |
| Gene symbol | Mechanism |
PTGS2 | Aberration of the Drug's Therapeutic Target |
PTGS2 | Unusual Activation of Pro-survival Pathway |
| Page: 1 |
Top |
MicroRNAs (miRNA) regulating PTGS2 |
| This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.) |
| Gene symbol | miRNA | Score | GeneBank accession |
| PTGS2 | hsa-miR-5692a | 99.9537 | NM_000963 |
| PTGS2 | hsa-miR-95-5p | 97.6874 | NM_000963 |
| PTGS2 | hsa-miR-1297 | 96.3232 | NM_000963 |
| PTGS2 | hsa-miR-4649-3p | 96.0086 | NM_000963 |
| PTGS2 | hsa-miR-6844 | 95.9109 | NM_000963 |
| PTGS2 | hsa-miR-3163 | 95.6798 | NM_000963 |
| PTGS2 | hsa-miR-26b-5p | 95.5199 | NM_000963 |
| PTGS2 | hsa-miR-26a-5p | 95.5199 | NM_000963 |
| PTGS2 | hsa-miR-4465 | 94.4681 | NM_000963 |
| PTGS2 | hsa-miR-5696 | 91.2235 | NM_000963 |
| PTGS2 | hsa-miR-101-3p | 91.1332 | NM_000963 |
| PTGS2 | hsa-miR-4282 | 88.4951 | NM_000963 |
| PTGS2 | hsa-miR-126-5p | 87.7153 | NM_000963 |
| PTGS2 | hsa-miR-513b-5p | 87.4398 | NM_000963 |
| PTGS2 | hsa-miR-4652-3p | 86.8027 | NM_000963 |
| PTGS2 | hsa-miR-548c-3p | 86.5508 | NM_000963 |
| PTGS2 | hsa-miR-29b-1-5p | 86.3118 | NM_000963 |
| PTGS2 | hsa-miR-4795-3p | 84.7627 | NM_000963 |
| PTGS2 | hsa-miR-125b-2-3p | 84.6881 | NM_000963 |
| PTGS2 | hsa-miR-542-3p | 84.6711 | NM_000963 |
| PTGS2 | hsa-miR-7-2-3p | 83.7771 | NM_000963 |
| PTGS2 | hsa-miR-7-1-3p | 83.7771 | NM_000963 |
| PTGS2 | hsa-miR-624-5p | 82.5128 | NM_000963 |
| PTGS2 | hsa-miR-3617-5p | 82.2264 | NM_000963 |
| PTGS2 | hsa-miR-641 | 82.2264 | NM_000963 |
| PTGS2 | hsa-miR-656-3p | 81.9553 | NM_000963 |
| PTGS2 | hsa-miR-664a-3p | 81.2801 | NM_000963 |
| PTGS2 | hsa-miR-4735-5p | 80.9973 | NM_000963 |
| Page: 1 |
Top |
Motifs and transcription factors (TFs) regulating PTGS2 |
| This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.) |
| Gene symbol | motif | TF_highConf |
| PTGS2 | transfac_pro__M05667 | ZNF35 (directAnnotation). |
| PTGS2 | transfac_pro__M05693 | ZNF30 (directAnnotation). |
| PTGS2 | transfac_pro__M06340 | ZNF790 (directAnnotation). |
| PTGS2 | transfac_pro__M04706 | RELA (directAnnotation). |
| PTGS2 | metacluster_92.3 | ZNF354A (directAnnotation). ZNF354B (inferredBy_Orthology). |
| PTGS2 | metacluster_5.1 | HIVEP1; HIVEP1; NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; NFKB2; NFKB2; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELB; RELB (directAnnotation). NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; REL; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELB; RELB; RELB (inferredBy_Orthology). |
| PTGS2 | transfac_pro__M05475 | ZBTB41 (directAnnotation). |
| PTGS2 | tfdimers__MD00143 | IKZF1; MZF1 (directAnnotation). |
| PTGS2 | transfac_pro__M05647 | ZNF875 (directAnnotation). |
| PTGS2 | transfac_pro__M06305 | ZNF583 (inferredBy_Orthology). |
| PTGS2 | transfac_pro__M05607 | MYBL1 (directAnnotation). |
| PTGS2 | transfac_pro__M04955 | ZBTB33 (directAnnotation). |
| PTGS2 | transfac_pro__M05791 | ZNF517 (directAnnotation). |
| PTGS2 | tfdimers__MD00192 | CHURC1 (directAnnotation). |
| PTGS2 | hocomoco__GMEB2_HUMAN.H11MO.0.D | GMEB2 (directAnnotation). |
| PTGS2 | tfdimers__MD00449 | REL; YY1 (directAnnotation). |
| PTGS2 | metacluster_155.13 | ZNF135 (directAnnotation). |
| PTGS2 | transfac_pro__M06159 | ZNF83 (directAnnotation). |
| PTGS2 | metacluster_135.11 | NR2C2 (directAnnotation). |
| PTGS2 | cisbp__M00341 | PAX6 (directAnnotation). |
| PTGS2 | jaspar__MA0185.1 | DEAF1 (inferredBy_Orthology). |
| PTGS2 | metacluster_61.1 | DEAF1; DEAF1 (directAnnotation). |
| PTGS2 | metacluster_133.1 | ZNF304; ZNF304; ZSCAN22 (directAnnotation). |
| PTGS2 | transfac_pro__M06550 | ZNF519 (directAnnotation). |
| PTGS2 | transfac_public__M00039 | CREB1 (directAnnotation). |
| PTGS2 | transfac_pro__M05905 | ZNF649 (directAnnotation). |
| Page: 1 |
Top |
Acts as a transcription factor |
| This table shows that this differential gene acts as a transcription factor. |
Top |
Acts as a drug target |
| This table shows that this differential gene acts as a drug target. |
| Target name | Drug name | Drug ID | Drug type |
| PTGS2 | "Menthyl salicylate" | DB11201 | small molecule |
| PTGS2 | "Mesalazine" | DB00244 | small molecule |
| PTGS2 | "Morniflumate" | DB09285 | small molecule |
| PTGS2 | "Nabiximols" | DB14011 | small molecule |
| PTGS2 | "Nabumetone" | DB00461 | small molecule |
| PTGS2 | "Naproxen" | DB00788 | small molecule |
| PTGS2 | "Nepafenac" | DB06802 | small molecule |
| PTGS2 | "Niflumic acid" | DB04552 | small molecule |
| PTGS2 | "Nimesulide" | DB04743 | small molecule |
| PTGS2 | "NS-398" | DB14060 | small molecule |
| PTGS2 | "Oxaprozin" | DB00991 | small molecule |
| PTGS2 | "Parecoxib" | DB08439 | small molecule |
| PTGS2 | "Phenyl salicylate" | DB11071 | small molecule |
| PTGS2 | "Phenylbutazone" | DB00812 | small molecule |
| PTGS2 | "Piroxicam" | DB00554 | small molecule |
| PTGS2 | "Pomalidomide" | DB08910 | small molecule |
| PTGS2 | "Propacetamol" | DB09288 | small molecule |
| PTGS2 | "Prostaglandin G2" | DB03866 | small molecule |
| PTGS2 | "Resveratrol" | DB02709 | small molecule |
| PTGS2 | "Robenacoxib" | DB11455 | small molecule |
| PTGS2 | "Rofecoxib" | DB00533 | small molecule |
| PTGS2 | "Salicylic acid" | DB00936 | small molecule |
| PTGS2 | "Salsalate" | DB01399 | small molecule |
| PTGS2 | "SC-236" | DB14059 | small molecule |
| PTGS2 | "Sulfasalazine" | DB00795 | small molecule |
| PTGS2 | "Sulindac" | DB00605 | small molecule |
| PTGS2 | "Suprofen" | DB00870 | small molecule |
| PTGS2 | "Talniflumate" | DB09295 | small molecule |
| PTGS2 | "Tenoxicam" | DB00469 | small molecule |
| PTGS2 | "Tiaprofenic acid" | DB01600 | small molecule |
| PTGS2 | "Tolfenamic acid" | DB09216 | small molecule |
| PTGS2 | "Tolmetin" | DB00500 | small molecule |
| PTGS2 | "Trolamine salicylate" | DB11079 | small molecule |
| PTGS2 | "Valdecoxib" | DB00580 | small molecule |
| Page: 1 2 |
| 1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
| 2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |
| 1 | Gene polymorphisms in dual antiplatelet therapy and the presence of hypo-attenuated leaflet thickening after transcatheter aortic valve replacement |
| 2 | "NSAID resistance in dysmenorrhea: epidemiology, causes, and treatment" |
| 3 | Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism |
| 4 | Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway |
| 5 | Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis |
Copyright 2022-Present -The University of Texas Health Science Center at Houston |